AN OPEN-LABEL RANDOMIZED MULTICENTER PHASE Ib/II TRIAL EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA

Brief description of study

The purpose of this study is to test the safety of mosunetuzumab at different dose levels when given in combination with polatuzumab vedotin and to find out what effects, good and/or bad, the study treatment has on you and your DLBCL or FL and to determine the most effective and safe dose; this is the dose-finding phase (Phase lb).


Clinical Study Identifier: s18-00326
ClinicalTrials.gov Identifier: NCT03671018
Principal Investigator: Catherine M Diefenbach.
Other Investigators: Maxim Kreditor, Bruce G Raphael, Kenneth B Hymes, Michael L. Grossbard, Mohammad Maher Abdul Hay, Jun Han Choi, Shella Saint Fleur-Lominy, David Kaminetzky, Tibor Moskovits.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.